Tag: Fenebrutinib relapsing MS patients
Fenebrutinib Shows Strong Disease Suppression in Relapsing MS Patients for 48 Weeks
Fenebrutinib Shows Remarkable Efficacy in Treating Relapsing MS Patients for 48 WeeksF. Hoffmann-La Roche Ltd recently released groundbreaking Phase II data demonstrating the exceptional...